The revolutionary emergence of new medications designed to combat obesity may have a significant impact on the consumption of alcohol, potentially affecting renowned brand Constellation Brands (STZ). This risk is already being observed within the food industry, particularly among companies that specialize in snacks and junk food. However, Constellation Brands, the powerful Mexican beer company behind popular products like Corona, Modelo, and Pacifico, can take strategic measures to mitigate any potential decrease in demand. It’s important to recognize that the weight-loss benefits provided by diabetes drugs such as Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro could pose challenges not only for alcohol manufacturers, but also for soda, snack food, and fast-food companies. Novo Nordisk has already received regulatory approval in the United States for the use of semaglutide, the active ingredient in Ozempic, as a prescription treatment for obesity. Marketed under the name Wegovy, semaglutide is proven to aid in weight loss. Moreover, Mounjaro—which contains the active ingredient tirzepatide—is expected to receive anti-obesity approval later this year.
Denial of responsibility! Vigour Times is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
